Added 1 day ago Drug news
Positive results from phase III VISIBLE 2 trial of subcutaneous Entyvio to treat moderate to severe Crohn's disease.- Takeda
-Takeda Pharmaceutical Company Limited announced results from the phase III VISIBLE 2 clinical trial evaluating the efficacy and safety of...
Added 3 days ago Drug news
Interim data from phase IIIb STARDUST study of Stelara shows clinical response in Crohns disease.- J&J Janssen Cilag
The Janssen Pharmaceutical Companies of Johnson & Johnson announced interim data from the Phase IIIb STARDUST study of Stelara (ustekinumab)...
Added 21 days ago Drug news
AstraZeneca will recover the global rights to brazikumab (formerly MEDI 2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Fibrinogen is important for blood clot formation and breakdown. It is the first coagulant factor to be reduced to critical levels during massive trauma, cardiac surgery and postpartum haemorrhage that involve excessive bleeding. Persistent fibrinogen deficiency can lead to bleeding complications and an increased risk in mortality. This learning zone looks at both congenital and acquired fibrinogen deficiencies including indications and techniques for diagnosis, trigger level for treatment and treatment options.
Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.
This guideline covers the management of ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support...
Added 6 months ago
Crohn's disease is a chronic inflammatory disease that mainly affects the gastrointestinal tract. The disease may be progressive in some people, and a proportion may develop extra-intestinal manifestations.
Added 7 years ago
Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition
Chronic diarrhoea is a common problem, hence clear guidance on investigations is required. This is an updated guideline from 2003 for the investigations of chronic diarrhoea...
Added 1 year ago
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
Background: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease.
Added 28 days ago
Area covered: We discuss the current considerations related to switching from reference products to biosimilars from a physician and patient perspective. We review the clinical data and real-life experience on switching patients...
Added 28 days ago
Introduction: To evaluate the possibility that switching from reference biologic medicines to biosimilars could lead to altered clinical outcomes, including enhanced immunogenicity, compromised safety, or diminished efficacy...
Added 28 days ago
Vedolizumab is a new medication being used for the treatment of Crohn's disease and Ulcerative colitis. It works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in...
Added 2 years ago
A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD) (BERGAMOT)
This is a multicenter, Phase 3, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderate to severely active CD...
Added 3 months ago
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor...
Added 2 years ago
A number of presentations and abstracts shared updates on the latest developments for new treatments and therapies, some of which are pioneering new modes of action. Here we look to the horizon, gaining insights into the latest data for novel treatments targeting Janus kinase (JAK) signalling, MAdCAM-1-mediated adhesion and the interleukin IL-23.